Stock 7776 CELLSEED INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials CellSeed Inc.

Equities

7776

JP3423530009

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-02 am EDT 		5-day change 1st Jan Change
210 JPY -1.87% Intraday chart for CellSeed Inc. +2.44% -22.51%
2023 CellSeed Inc. announced that it has received ¥2.001 million in funding from Barclays Bank PLC, Investment Arm CI
2023 CellSeed Inc. announced that it expects to receive ¥2.001 million in funding from Barclays Bank PLC, Investment Arm CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization 1 4,939 5,273 7,641 6,623 3,776 3,268
Enterprise Value (EV) 1 3,883 3,923 6,584 5,558 2,476 2,497
P/E ratio -3.46 x -4.95 x 59.3 x -7.74 x -4.47 x -3.46 x
Yield - - - - - -
Capitalization / Revenue 49.4 x 62 x 7.45 x 24.1 x 19 x 20.3 x
EV / Revenue 38.8 x 46.2 x 6.42 x 20.2 x 12.4 x 15.5 x
EV / EBITDA -2.76 x -3.85 x 45.7 x -7.16 x -3.49 x -2.89 x
EV / FCF -3.16 x -8.96 x -18.3 x -19 x -5.86 x -4.3 x
FCF Yield -31.6% -11.2% -5.46% -5.26% -17.1% -23.3%
Price to Book 4.25 x 4.2 x 5.42 x 4.97 x 2.59 x 3.18 x
Nbr of stocks (in thousands) 9,214 11,414 11,439 12,860 15,287 17,759
Reference price 2 536.0 462.0 668.0 515.0 247.0 184.0
Announcement Date 3/30/17 3/30/18 3/29/19 3/30/20 3/29/21 3/28/22
1JPY in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales 1 100 85 1,026 275 199 161
EBITDA 1 -1,406 -1,020 144 -776 -710 -863
EBIT 1 -1,414 -1,024 140 -781 -719 -865
Operating Margin -1,414% -1,204.71% 13.65% -284% -361.31% -537.27%
Earnings before Tax (EBT) 1 -1,415 -964 139 -782 -780 -911
Net income 1 -1,414 -966 129 -782 -783 -914
Net margin -1,414% -1,136.47% 12.57% -284.36% -393.47% -567.7%
EPS 2 -154.9 -93.25 11.27 -66.56 -55.25 -53.15
Free Cash Flow 1 -1,229 -438 -359.5 -292.1 -422.4 -580.6
FCF margin -1,228.75% -515.29% -35.04% -106.23% -212.25% -360.64%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/30/17 3/30/18 3/29/19 3/30/20 3/29/21 3/28/22
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 - - - - - -
Net Cash position 1 1,056 1,350 1,057 1,065 1,300 771
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1,229 -438 -360 -292 -422 -581
ROE (net income / shareholders' equity) -79.6% -79.8% 9.67% -56.7% -54.6% -71.7%
ROA (Net income/ Total Assets) -46.1% -44.1% 5.56% -32.1% -27.6% -33.8%
Assets 1 3,066 2,192 2,320 2,437 2,842 2,703
Book Value Per Share 2 126.0 110.0 123.0 104.0 95.30 57.80
Cash Flow per Share 2 115.0 118.0 92.20 82.00 91.20 52.40
Capex 1 343 5 1 13 7 91
Capex / Sales 343% 5.88% 0.1% 4.73% 3.52% 56.52%
Announcement Date 3/30/17 3/30/18 3/29/19 3/30/20 3/29/21 3/28/22
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CELLSEED INC. Stock CellSeed Inc.
-22.51% 43.93M
CSL LIMITED Stock CSL Limited
-3.79% 87.06B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.45% 40.25B
BIOGEN INC. Stock Biogen Inc.
-16.44% 31.09B
UCB Stock UCB
+52.66% 24.74B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.15% 15.91B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
INCYTE CORPORATION Stock Incyte Corporation
-15.05% 11.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.73B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 7776 Stock
  4. Financials CellSeed Inc.